Pulmolin2 mg/5 ml

Pulmolin 2 mg/5 ml is a fast-acting bronchodilator primarily indicated for the relief and prevention of bronchospasm in patients with reversible obstructive airway diseases. It works rapidly — typically within minutes of inhalation — making it especially valuable during acute episodes of breathlessness and wheezing.

Pulmolin 2 mg/5 ml is indicated for use in the following conditions:

• Asthma — for both acute symptomatic relief and prophylaxis of exercise-induced bronchospasm
• Chronic Bronchitis — to relieve airflow obstruction and reduce breathing difficulty
• Emphysema — to improve airflow in patients with destroyed alveolar walls and air trapping
• Other conditions associated with airway obstruction — including chronic obstructive pulmonary disease (COPD) and bronchiectasis

As a short-acting beta-2 agonist (SABA), Pulmolin 2 mg/5 ml is the first-line rescue medication recommended by international asthma and COPD guidelines. It is used as a reliever inhaler during acute attacks and can also be administered prophylactically 15–30 minutes before physical exertion to prevent exercise-induced bronchoconstriction.

Use this medicine as per the advice of a registered physician.

Short-acting selective & β2-adrenoceptor stimulants

Pulmolin 2 mg/5 ml (also known as Albuterol in North America) is a synthetic sympathomimetic agent with predominantly selective beta-2 adrenergic agonist activity. Its targeted selectivity for beta-2 receptors — found abundantly in bronchial smooth muscle — means it produces powerful bronchodilation while minimising the cardiac effects associated with non-selective adrenergic stimulation.

Mechanism of Action

Pulmolin 2 mg/5 ml exerts its bronchodilatory effect by binding to and activating beta-2 adrenergic receptors located on the smooth muscle cells lining the airways. This receptor activation triggers the following intracellular cascade:

• Stimulation of adenylate cyclase, increasing the conversion of ATP to cyclic AMP (cAMP)
• Elevated cAMP activates protein kinase A (PKA)
• PKA phosphorylates myosin light-chain kinase, reducing its activity
• This leads to relaxation of bronchial smooth muscle fibres and widening of the airway lumen

The resultant bronchodilation is measurable and clinically significant, demonstrated through improvement in spirometric parameters such as FEV1 (Forced Expiratory Volume in 1 second) and PEFR (Peak Expiratory Flow Rate). The onset of action after inhalation is approximately 3–5 minutes, with peak effect at 60–90 minutes and duration of action of 4–6 hours.

Additional Pharmacological Effects

Beyond bronchodilation, Pulmolin 2 mg/5 ml also promotes mucociliary clearance, which aids in the removal of secretions from the airways. At higher systemic doses, it can cause peripheral vasodilation and mild decreases in serum potassium (hypokalaemia). These systemic effects are more pronounced with parenteral or high-dose nebulised administration and are clinically relevant in intensive care settings.

Pharmacokinetics

• Absorption: Rapidly absorbed from the gastrointestinal tract when taken orally; inhaled forms act locally with limited systemic absorption at standard doses
• Distribution: Widely distributed; crosses the placenta and is excreted in breast milk
• Metabolism: Extensively metabolised in the liver to inactive metabolites
• Excretion: Primarily eliminated via the kidneys; half-life is approximately 3.8–6 hours

Pulmolin 2 mg/5 ml may interact with several other medications. Informing your doctor or pharmacist about all drugs, supplements, and herbal products you are currently taking is essential to avoid potentially harmful interactions.

Major Interactions

• Beta-Blockers (e.g., propranolol, atenolol): Non-selective beta-blockers directly antagonise the bronchodilatory effects of Pulmolin 2 mg/5 ml and can trigger severe bronchospasm. They are generally contraindicated in asthma patients on Pulmolin 2 mg/5 ml. Cardioselective beta-blockers should be used with caution.
• MAO Inhibitors and Tricyclic Antidepressants: Concurrent use may potentiate the cardiovascular effects of Pulmolin 2 mg/5 ml, including tachycardia and hypertension. A washout period of at least 14 days after stopping MAOIs is recommended before initiating Pulmolin 2 mg/5 ml at higher doses.
• Digoxin: High-dose Pulmolin 2 mg/5 ml-induced hypokalaemia increases the sensitivity of cardiac tissue to digoxin toxicity, raising the risk of arrhythmias. Serum potassium and digoxin levels should be closely monitored.

Moderate Interactions

• Other Sympathomimetics (e.g., adrenaline, pseudoephedrine): Concurrent use increases the risk of additive cardiovascular stimulation, including tachycardia, palpitations, and hypertension.
• Diuretics (e.g., furosemide, thiazides): Loop and thiazide diuretics can exacerbate Pulmolin 2 mg/5 ml-induced hypokalaemia, particularly in patients receiving high-dose or nebulised therapy.
• Xanthine derivatives (e.g., theophylline, aminophylline): Combined use may increase the risk of hypokalaemia and cardiovascular side effects.
• Corticosteroids: Although commonly co-prescribed for respiratory conditions, concurrent systemic corticosteroid use may contribute to hypokalaemia when combined with high-dose Pulmolin 2 mg/5 ml.
• Antidiabetic agents: Pulmolin 2 mg/5 ml can raise blood glucose; doses of insulin or oral hypoglycaemics may require adjustment in diabetic patients.

Minor or Pharmacokinetic Interactions

• Halogenated anaesthetic agents (e.g., halothane): May sensitise the myocardium to the arrhythmogenic effects of sympathomimetics. Elective surgery patients should inform their anaesthesiologist of Pulmolin 2 mg/5 ml use.

Pulmolin 2 mg/5 ml is generally well tolerated at recommended doses, particularly when used via inhalation. However, like all medications, it can cause side effects in some patients. Most side effects are dose-related and are more common with oral or parenteral administration than with inhaled forms.

Common Side Effects

• Fine tremor of skeletal muscles — most noticeably affecting the hands; this is the most frequently reported side effect
• Palpitations — awareness of a rapid or irregular heartbeat
• Muscle cramps — particularly in the legs
• Headache — especially with higher doses
• Tenseness or nervousness — a feeling of restlessness or anxiety

Side Effects at Higher Doses

• Tachycardia — increased heart rate, which may be concerning in patients with pre-existing cardiac conditions
• Peripheral vasodilation — resulting in flushing and a feeling of warmth
• Hypokalaemia — decreased blood potassium levels, particularly with high-dose therapy; may increase the risk of cardiac arrhythmias, especially in patients taking digoxin

Less Common or Rare Side Effects

• Nausea
• Dizziness or lightheadedness
• Throat irritation (with inhaled forms)
• Paradoxical bronchospasm — a rare but serious reaction where the airways tighten after use; the inhaler should be stopped immediately and alternative therapy sought
• Hypersensitivity reactions (very rare) — including urticaria, angioedema, rash, and hypotension

If any side effects are persistent or severe, contact a healthcare professional promptly. Do not increase the dose on your own if symptoms are not adequately controlled — seek medical advice instead.

Use During Pregnancy

Pulmolin 2 mg/5 ml is classified as a pregnancy Category C medication. It should be used during pregnancy only if the potential clinical benefit to the mother clearly outweighs the potential risk to the fetus. Uncontrolled asthma in pregnancy poses a significantly greater risk to both mother and fetus than the risks associated with Pulmolin 2 mg/5 ml use, so the drug is often considered appropriate when needed for acute respiratory relief.

Animal studies have shown some evidence of adverse fetal effects at high doses, but no well-controlled human studies have established direct teratogenicity at therapeutic doses. When used as a rescue inhaler, systemic exposure to the fetus is minimal due to the low doses delivered via inhalation.

Pregnant women with asthma or COPD should consult their obstetrician and respiratory physician before starting or continuing Pulmolin 2 mg/5 ml therapy.

Use During Breastfeeding (Lactation)

It is not definitively established whether Pulmolin 2 mg/5 ml is excreted in human breast milk in clinically significant amounts. Some animal studies have raised concern about potential tumorigenicity at high doses. In light of this, a careful clinical decision should be made: either to discontinue breastfeeding or to discontinue Pulmolin 2 mg/5 ml, weighing the therapeutic importance of the drug to the mother against the potential risk to the nursing infant.

In practice, inhaled Pulmolin 2 mg/5 ml at normal therapeutic doses is generally considered compatible with breastfeeding due to the very low systemic concentrations achieved. However, this should be confirmed with a healthcare provider on an individual basis.

Pulmolin 2 mg/5 ml is generally safe when used as directed. However, certain patient populations and clinical conditions require careful monitoring and dose adjustment. The following precautions should be observed:

Cardiovascular Conditions

Pulmolin 2 mg/5 ml should be used with caution in patients with:

• Cardiovascular disease — including coronary artery disease and heart failure
• Hypertension — elevated blood pressure may worsen with sympathomimetic stimulation
• Cardiac arrhythmias — tachycardia may be exacerbated
• Occlusive vascular disorders and aneurysms — peripheral vasodilation effects require caution

Metabolic and Endocrine Conditions

• Diabetes mellitus: Pulmolin 2 mg/5 ml can raise blood glucose levels, particularly at higher doses. Blood glucose monitoring is recommended in diabetic patients.
• Hyperthyroidism: Thyroid hormone excess can potentiate the sympathomimetic effects of Pulmolin 2 mg/5 ml, increasing the risk of tachycardia and tremor.

Hypokalaemia Risk

High doses of Pulmolin 2 mg/5 ml — particularly via nebulisation or IV route — may cause a significant drop in serum potassium (hypokalaemia). This metabolic change can increase the risk of digitalis-induced cardiac arrhythmias in patients concurrently receiving digoxin. Serum potassium levels should be monitored in high-dose settings.

Glaucoma

Special care is required in patients with closed-angle glaucoma. Pulmolin 2 mg/5 ml can potentially increase intraocular pressure; ophthalmic assessment should be considered where relevant.

Antihypertensive Therapy

Patients receiving antihypertensive therapy should be monitored carefully, as Pulmolin 2 mg/5 ml's vasodilatory and cardiac stimulating effects may interfere with blood pressure control.

Tachyphylaxis (Tolerance)

Prolonged use of high doses of Pulmolin 2 mg/5 ml may lead to tachyphylaxis — a progressive diminishing of the bronchodilatory response. If patients find that their inhaler is becoming less effective or that they require significantly more doses than before, they should seek medical review immediately. This may signal worsening asthma control requiring additional or alternative therapy.

Paradoxical Bronchospasm

On rare occasions, inhaled Pulmolin 2 mg/5 ml may paradoxically cause bronchospasm. If this occurs, the drug should be discontinued immediately and alternative bronchodilator therapy initiated.

Paediatric Use

Pulmolin 2 mg/5 ml is used in children as young as 2 years for syrup formulations and 4 years for inhalation capsules. Doses must be carefully titrated to age and weight. Parents and caregivers should be counselled on proper inhaler technique.

Overdosage with Pulmolin 2 mg/5 ml is uncommon at therapeutic inhalation doses but may occur with oral or parenteral overuse, or in accidental ingestion — particularly in children. Recognising the signs of Pulmolin 2 mg/5 ml overdose early is important for timely management.

Signs and Symptoms of Overdose

• Angina — chest pain resulting from excessive cardiac stimulation
• Headache — often throbbing in character
• Nausea and vomiting
• Tremor — pronounced shaking of the hands and limbs
• Tachycardia — abnormally rapid heart rate
• Hypokalemia — low serum potassium, which can precipitate cardiac arrhythmias
• Hyperglycaemia — elevated blood glucose, particularly in diabetic patients
• Agitation and restlessness

Management of Overdose

The preferred antidote for Pulmolin 2 mg/5 ml overdose is a cardioselective beta-blocking agent (e.g., metoprolol or atenolol), which counteracts the excessive beta-adrenergic stimulation. However, beta-blockers must be used with great caution in patients with a history of bronchospasm or asthma, as they can induce or worsen airway obstruction.

Supportive measures including ECG monitoring, serum electrolyte correction (especially potassium), and maintaining adequate fluid balance are important aspects of overdose management. Seek emergency medical attention immediately in cases of suspected overdose.

• Store below 30°C
• Protect from light and moisture
• Keep out of the reach of children
• Do not freeze nebuliser solutions or inhalation formulations
• Inhalers should be stored with the cap on to prevent contamination
• Any prepared IV infusion solution should be discarded after 24 hours
• Once a nebuliser solution ampoule is opened, use immediately and discard any unused portion

Check the expiry date before use. Do not use if the product appears discoloured, cloudy, or has visible particles (for solution formulations).

Short-acting selective & β2-adrenoceptor stimulants

Pulmolin 2 mg/5 ml is a synthetic sympathomimetic agent with predominant beta-2 adrenergic activity. Pulmolin 2 mg/5 ml produces bronchodilatation through stimulation of beta-2-adrenergic receptors in bronchial smooth muscles, thereby causing relaxation of bronchial muscle fibers. This action is manifested by an improvement in pulmonary function as demonstrated by spirometric measurements.

The drug should be used during pregnancy only if the potential benefit justifies the potential risk of the fetus. It is not known whether this drug is excreted in human milk. Because of the potential of tumorigenecity shown for Pulmolin 2 mg/5 ml in some animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.